<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04174547</url>
  </required_header>
  <id_info>
    <org_study_id>TRS-2018-00000745</org_study_id>
    <nct_id>NCT04174547</nct_id>
  </id_info>
  <brief_title>An European Platform for Translational Research in Myelodysplastic Syndromes</brief_title>
  <official_title>An Integrated European Platform to Conduct Translational Studies in Myelodysplastic Syndromes Based on the EuroBloodNet Infrastructure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Clinico Humanitas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Clinico Humanitas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale Myelodysplastic syndromes (MDS) are rare cancers with unmet medical needs. Study of
      MDS has been rapidly transformed by genome characterization.

      The investigators hypothesize that comprehensive analyses of large patient population will
      allow to correctly estimate the effect of each mutation on clinical outcomes, and that niche
      factors and immune dysfunctions may influence the development of MDS, clonal evolution and
      response to treatments

      Aims

      1- Investigate gene mutations, niche factors and immune dysfunctions influencing the
      development of MDS, and define biomarkers for early identification of individuals at risk; 2-
      Develop prognostic models for MDS patients through integration of comprehensive
      genomic/clinical information; 3- Define biomarkers to better stratify the individual
      probability of response to specific treatments

      Methods EuroBloodNet, the European Reference Network in rare hematological diseases, will
      provide a basis for research activities. Study of genomic features of clonal dominance in
      elderly subjects enrolled in large population-based studies and description of the dynamics
      of clonal establishment and evolution; study of bone marrow microenvironment to identify
      immune dysfunctions influencing MDS development. Development of inclusive statistical models
      to accurately predict clinical outcome at individual level, based on large MDS populations
      with comprehensive genomic/clinical data. Finally, analysis of mutational screening and
      immune profiles from patients enrolled in prospective trials, to provide evidence on
      genetic/immunologic profiles associated with probability of response to specific compounds

      Expected results To characterize how clonal hematopoiesis relates to the induction of MDS
      clinical phenotype, and to test the utility of gene sequencing to detect subjects at risk of
      developing MDS. To define effective prognostic systems and biomarkers to stratify the
      individual probability of response to treatment
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MDS typically occurs in elderly people and a portion of these subjects evolve into acute
      myeloid leukemia (AML). The natural history of MDS is highly heterogeneous, and therefore a
      risk-adapted treatment strategy is mandatory.

      The presence of mutations in a given individual has only limited predictive power, as
      conversion to MDS is rare regardless of mutation status. In addition, in patients with overt
      MDS, genetic abnormalities explain only a proportion of the total hazard for survival,
      meaning that a large percentage is still associated with clinical and non-mutational factors.
      Comprehensive analyses of large patient populations are warranted to correctly estimate the
      independent effect of each mutation on clinical outcome and response to treatment.

      Moreover, environmental factors influencing the development of MDS and the probability of
      response to specific treatments are to be characterized. They include alterations in the
      immune system. In this context, a significant association was found between autoimmune
      disorders and MDS, and activation of the inflammasome may contribute to MDS development

      AIMS 1- Investigate gene mutations, niche factors and immune dysfunctions influencing the
      development of MDS, and define biomarkers for early identification of individuals at risk; 2-
      Develop prognostic models for MDS patients through integration of comprehensive
      genomic/clinical information; 3- Define biomarkers to better stratify the individual
      probability of response to specific treatments

      EXPERIMENTAL DESIGN

      AIM1

      1a) The investigators will analyze the genomic features of clonal dominance and ineffective
      hematopoiesis in elderly subjects enrolled in different population-based studies.

      Peripheral blood samples will be available for biological investigations. A low-cost,
      high-throughput platform for mutation screening of 72 genes known to be relevant in MDS will
      be used.

      1b) In order to gain further insight into the MDS genetic heterogeneity, the investigators
      will perform DNA sequencing in hematopoietic progenitors single cells to clarify the clonal
      architecture of marrow dysplasia in HSC, the dynamics of clonal establishment and expansion
      during hematopoietic differentiation, and their relationship with the disease phenotype and
      evolution

      1c) In selected elderly individuals, the investigators will study the transcriptome (RNA
      sequencing) of isolated mesenchymal stromal cells (MSC) and marrow microenvironment (i.e.,
      innate ad adaptive immunity) with the aim to identify niche factors that may influence the
      development of a MDS phenotype in elderly subjects with clonal hematopoiesis. Moreover, in
      patients suffering from both MDS and autoimmune disorder, the investigators will analyze
      immunological parameters. They will be compared with those of patients with MDS but without
      immune disorder, and patients with immune disorders without MDS

      AIM2

      In myeloid malignancies, it was shown that large knowledge banks of matched genomic-clinical
      data can improve clinical decision-making.

      In the present project, basing on large MDS populations with comprehensive genomic and
      clinical data available within EuroBloodNet network (data on &gt;3000 patients will be
      available), the investigators will develop inclusive, multistage statistical models (Bayesian
      network analysis and clustering) to accurately predict clinical outcomes in MDS at
      individual-patient level. The investigators plan to define 2 homogenous clinical cohorts in
      order to define distinct patterns and genetic groups within MDS and to independently validate
      their predictive value. As a research tool, the investigators plan to create a prototype
      portal within our EuroBloodNet website that allows outcome predictions to be generated based
      on this data set for user-defined constellations of genomic features and clinical variables.
      The reliability of this tool on clinical decision making will be tested in a prospective
      observational trial in the context of EuroBloodNet

      AIM3

      The investigators will analyze the mutational status and immune landscape associated with
      response to HMA in MDS patients enrolled in prospective clinical trials conducted within the
      EuroBloodNet network. Patients treated with azacitidine from prospective studies will be
      available for biological investigations to define biomarkers associated with clinical
      response. Validation of biomarkers will then be performed in an independent cohort. In all
      these studies, biobanking of bone marrow (BM) and peripheral blood (PB) samples has been
      systematically performed, providing a unique resource to be investigated within this
      proposal. Data on mutational screening and immune profiles are already available in most
      patients, and were obtained by comparable methods. For mutation screening, a NGS approach
      covering key genes involved in myeloid malignancies and the response to HMA was used. For a
      comprehensive immunological characterization of T lymphocytes, NK cells and ILC cells,
      standardized flow cytometric protocols were used, which will provide novel insights into
      frequency, differentiation and activity of these cells in response to therapy. Complementary
      immunoassays based on Luminex technology will be used to quantify secretory proteins
      (cytokines, chemokines, growth factors) in BM and PB plasma samples.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>DNA mutations in hematopoietic cells</measure>
    <time_frame>0-24 months</time_frame>
    <description>The investigotors will study the prevalence and type of somatic mutations by a low-cost, high-throughput platform including 72 genes, relevant in myeloid neoplasms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>RNA expression on hematopoietic progenitors and mesenchymal stromal cells</measure>
    <time_frame>6-24 months</time_frame>
    <description>The investigators will study the genes diffentially expressed between cell populations of interest and normal controls</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Predictive biomarkers for survival and response to treatment</measure>
    <time_frame>0-30 months</time_frame>
    <description>The investigators will define, by innovative bayesian and clustering models, independent clinical and molecular factors associated to the probability of survival and response to specific treatments.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency and function of T lymphocytes, NK cells and ILC cells</measure>
    <time_frame>6-30 motnhs</time_frame>
    <description>The investigators will analyse by flow-cytometry the frequency of T lymphocytes, NK cells and ILC cells during different disease stages and in response to therapy.
Complementary immunoassays based on Luminex technology will be used to quantify secretory proteins (cytokines, chemokines, growth factors).</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">8670</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Clonal hematopoiesis (AIM 1)</arm_group_label>
    <description>The investigators will analyze the genomic features of clonal dominance and ineffective hematopoiesis in elderly subjects enrolled in two population-based studies: &quot;Health and Anemia&quot; study [Haematologica 2010;95:1849], and &quot;Monzino 80-plus&quot; study [BMC Neurol.2011;11:54, validation cohort]. Overall in 5000 subjects aged &gt;65y peripheral blood samples (in some cases collected at different time points) will be available for biological investigations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Innovative predictive models in MDS (AIM2)</arm_group_label>
    <description>The investigators will base on large retrospectove adult MDS population with comprehensive genomic and clinical data available within EuroBloodNet network (data on 3000 patients will be available), to accurately predict clinical outcomes in MDS at individual-patient level.
The investigators plan to define 2 homogenous clinical cohorts (learning and testing cohort at 2:1 ratio) in order to define distinct patterns and genetic groups within MDS and to independently validate their predictive value.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Predictive biomarkers in MDS (AIM3)</arm_group_label>
    <description>The investigators will analyze MDS patients enrolled in prospective clinical trials conducted within the EuroBloodNet network. Overall 350 patients treated with azacitidine from prospective studies (VidazaAllotrial, RELAZA02 trial, AZA-Ida study, intensive AZA study) will be available for biological investigations to define biomarkers associated with clinical response. Validation of biomarkers will then be performed in an independent cohort including 320 patients (AZA-PLUS trial). In all these studies, biobanking of bone marrow (BM) and peripheral blood (PB) samples has been systematically performed, providing a unique resource to be investigated within this proposal.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Peripheral blood and marrow samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        AIM 1 Individuals enrolled in the population-based &quot;Health and Anemia&quot; and &quot;Monzino 80+&quot;
        studies, with biological samples available at prevalence day

        AIM 2 Patients receiving a diagnosis of MDS within EuroBloodNet clinical network, for which
        complete information on clinical and DNA mutational screening data is available

        AIM 3

          -  Testing cohort: MDS patients treated with HMAs within prospective clinical trials
             (VidazaAllotrial, RELAZA02 trial, AZA-Ida study, intensive AZA study), with biological
             samples availability

          -  Validation cohort: adults MDS patients treated with HMAs within the prospective
             clinical trial AZA-PLUS, with biological samples availability
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        AIM 1

        Inclusion Criteria:

        - Individuals aged 65 years or older from population-based studies (retrospective cohort)

        Exclusion Criteria:

        - lack of biological samples availability

        AIM 2

        Inclusion Criteria:

        - adults patients (&gt;18 years) with a diagnosis of MDS according to WHO criteria
        (retrospective cohort)

        Exclusion Criteria:

        - lack of availability of information on clinical and DNA mutational screening data

        AIM 3

        Inclusion Criteria:

        - adults patients (&gt;18 years) with a diagnosis of MDS according to WHO criteria and treated
        with HMAs

        Exclusion Criteria:

        - lack of biological samples availability
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matteo Della Porta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HUMANITAS Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matteo Della Porta, MD</last_name>
    <phone>+39 02 8224 7668</phone>
    <email>matteo.della_porta@hunimed.eu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria Elena Bicchieri, PhD</last_name>
    <email>marilena.bicchieri@cancercenter.humanitas.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service d'hématologie séniors - Hôpital St Louis / Université Paris 7</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Fenaux, MD</last_name>
      <phone>(0)171207018</phone>
      <phone_ext>+33</phone_ext>
      <email>pierre.fenaux@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Leipzig Medical Center</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uwe Platzbecker, MD</last_name>
      <phone>(0) 3514582583</phone>
      <phone_ext>+49</phone_ext>
      <email>Uwe.Platzbecker@medizin.uni-leipzig.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>Milan</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Josep Carreras Leukaemia Research Institute (IJC)</name>
      <address>
        <city>Barcelona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesc Sole, MD</last_name>
      <phone>935572806</phone>
      <phone_ext>+34</phone_ext>
      <email>fsole@carrerasresearch.org</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Adès L, Itzykson R, Fenaux P. Myelodysplastic syndromes. Lancet. 2014 Jun 28;383(9936):2239-52. doi: 10.1016/S0140-6736(13)61901-7. Epub 2014 Mar 21. Review.</citation>
    <PMID>24656536</PMID>
  </reference>
  <reference>
    <citation>Malcovati L, Hellström-Lindberg E, Bowen D, Adès L, Cermak J, Del Cañizo C, Della Porta MG, Fenaux P, Gattermann N, Germing U, Jansen JH, Mittelman M, Mufti G, Platzbecker U, Sanz GF, Selleslag D, Skov-Holm M, Stauder R, Symeonidis A, van de Loosdrecht AA, de Witte T, Cazzola M; European Leukemia Net. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013 Oct 24;122(17):2943-64. doi: 10.1182/blood-2013-03-492884. Epub 2013 Aug 26.</citation>
    <PMID>23980065</PMID>
  </reference>
  <reference>
    <citation>Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstöcker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012 Sep 20;120(12):2454-65. Epub 2012 Jun 27.</citation>
    <PMID>22740453</PMID>
  </reference>
  <reference>
    <citation>Schanz J, Tüchler H, Solé F, Mallo M, Luño E, Cervera J, Granada I, Hildebrandt B, Slovak ML, Ohyashiki K, Steidl C, Fonatsch C, Pfeilstöcker M, Nösslinger T, Valent P, Giagounidis A, Aul C, Lübbert M, Stauder R, Krieger O, Garcia-Manero G, Faderl S, Pierce S, Le Beau MM, Bennett JM, Greenberg P, Germing U, Haase D. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012 Mar 10;30(8):820-9. doi: 10.1200/JCO.2011.35.6394. Epub 2012 Feb 13.</citation>
    <PMID>22331955</PMID>
  </reference>
  <reference>
    <citation>Nomdedeu M, Calvo X, Pereira A, Carrió A, Solé F, Luño E, Cervera J, Vallespí T, Muñoz C, Gómez C, Arias A, Such E, Sanz G, Grau J, Insunza A, Calasanz MJ, Ardanaz MT, Hernández-Rivas JM, Azaceta G, Álvarez S, Sánchez J, Martín ML, Bargay J, Gómez V, Cervero CJ, Allegue MJ, Collado R, Campo E, Esteve J, Nomdedeu B, Costa D; Spanish Group of Myelodysplastic Syndromes. Prognostic impact of chromosomal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemia patients. A study by the spanish group of myelodysplastic syndromes. Genes Chromosomes Cancer. 2016 Apr;55(4):322-7. doi: 10.1002/gcc.22333. Epub 2015 Dec 22.</citation>
    <PMID>26690722</PMID>
  </reference>
  <reference>
    <citation>Schanz J, Tüchler H, Solé F, Mallo M, Luño E, Cervera J, Grau J, Hildebrandt B, Slovak ML, Ohyashiki K, Steidl C, Fonatsch C, Pfeilstöcker M, Nösslinger T, Valent P, Giagounidis A, Aul C, Lübbert M, Stauder R, Krieger O, Le Beau MM, Bennett JM, Greenberg P, Germing U, Haase D. Monosomal karyotype in MDS: explaining the poor prognosis? Leukemia. 2013 Oct;27(10):1988-95. doi: 10.1038/leu.2013.187. Epub 2013 Jun 21.</citation>
    <PMID>23787396</PMID>
  </reference>
  <reference>
    <citation>Valcárcel D, Ademà V, Solé F, Ortega M, Nomdedeu B, Sanz G, Luño E, Cañizo C, de la Serna J, Ardanaz M, Marco V, Collado R, Grau J, Montoro J, Mallo M, Vallespí T. Complex, not monosomal, karyotype is the cytogenetic marker of poorest prognosis in patients with primary myelodysplastic syndrome. J Clin Oncol. 2013 Mar 1;31(7):916-22. doi: 10.1200/JCO.2012.41.6073. Epub 2013 Jan 14.</citation>
    <PMID>23319689</PMID>
  </reference>
  <reference>
    <citation>Della Porta MG, Alessandrino EP, Bacigalupo A, van Lint MT, Malcovati L, Pascutto C, Falda M, Bernardi M, Onida F, Guidi S, Iori AP, Cerretti R, Marenco P, Pioltelli P, Angelucci E, Oneto R, Ripamonti F, Bernasconi P, Bosi A, Cazzola M, Rambaldi A; Gruppo Italiano Trapianto di Midollo Osseo. Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. Blood. 2014 Apr 10;123(15):2333-42. doi: 10.1182/blood-2013-12-542720. Epub 2014 Feb 20.</citation>
    <PMID>24558201</PMID>
  </reference>
  <reference>
    <citation>Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, Yoon CJ, Ellis P, Wedge DC, Pellagatti A, Shlien A, Groves MJ, Forbes SA, Raine K, Hinton J, Mudie LJ, McLaren S, Hardy C, Latimer C, Della Porta MG, O'Meara S, Ambaglio I, Galli A, Butler AP, Walldin G, Teague JW, Quek L, Sternberg A, Gambacorti-Passerini C, Cross NC, Green AR, Boultwood J, Vyas P, Hellstrom-Lindberg E, Bowen D, Cazzola M, Stratton MR, Campbell PJ; Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013 Nov 21;122(22):3616-27; quiz 3699. doi: 10.1182/blood-2013-08-518886. Epub 2013 Sep 12.</citation>
    <PMID>24030381</PMID>
  </reference>
  <reference>
    <citation>Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D, Pellagatti A, Wainscoat JS, Hellstrom-Lindberg E, Gambacorti-Passerini C, Godfrey AL, Rapado I, Cvejic A, Rance R, McGee C, Ellis P, Mudie LJ, Stephens PJ, McLaren S, Massie CE, Tarpey PS, Varela I, Nik-Zainal S, Davies HR, Shlien A, Jones D, Raine K, Hinton J, Butler AP, Teague JW, Baxter EJ, Score J, Galli A, Della Porta MG, Travaglino E, Groves M, Tauro S, Munshi NC, Anderson KC, El-Naggar A, Fischer A, Mustonen V, Warren AJ, Cross NC, Green AR, Futreal PA, Stratton MR, Campbell PJ; Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011 Oct 13;365(15):1384-95. doi: 10.1056/NEJMoa1103283. Epub 2011 Sep 26.</citation>
    <PMID>21995386</PMID>
  </reference>
  <reference>
    <citation>Della Porta MG, Tuechler H, Malcovati L, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstöcker M, Sekeres MA, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D, Greenberg PL, Cazzola M. Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM). Leukemia. 2015 Jul;29(7):1502-13. doi: 10.1038/leu.2015.55. Epub 2015 Feb 27.</citation>
    <PMID>25721895</PMID>
  </reference>
  <reference>
    <citation>Della Porta MG, Travaglino E, Boveri E, Ponzoni M, Malcovati L, Papaemmanuil E, Rigolin GM, Pascutto C, Croci G, Gianelli U, Milani R, Ambaglio I, Elena C, Ubezio M, Da Via' MC, Bono E, Pietra D, Quaglia F, Bastia R, Ferretti V, Cuneo A, Morra E, Campbell PJ, Orazi A, Invernizzi R, Cazzola M; Rete Ematologica Lombarda (REL) Clinical Network. Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes. Leukemia. 2015 Jan;29(1):66-75. doi: 10.1038/leu.2014.161. Epub 2014 May 20.</citation>
    <PMID>24935723</PMID>
  </reference>
  <reference>
    <citation>Della Porta MG, Jackson CH, Alessandrino EP, Rossi M, Bacigalupo A, van Lint MT, Bernardi M, Allione B, Bosi A, Guidi S, Santini V, Malcovati L, Ubezio M, Milanesi C, Todisco E, Voso MT, Musto P, Onida F, Iori AP, Cerretti R, Grillo G, Molteni A, Pioltelli P, Borin L, Angelucci E, Oldani E, Sica S, Pascutto C, Ferretti V, Santoro A, Bonifazi F, Cazzola M, Rambaldi A. Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System. Leukemia. 2017 Nov;31(11):2449-2457. doi: 10.1038/leu.2017.88. Epub 2017 Mar 21.</citation>
    <PMID>28321120</PMID>
  </reference>
  <reference>
    <citation>Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, Lindsley RC, Mermel CH, Burtt N, Chavez A, Higgins JM, Moltchanov V, Kuo FC, Kluk MJ, Henderson B, Kinnunen L, Koistinen HA, Ladenvall C, Getz G, Correa A, Banahan BF, Gabriel S, Kathiresan S, Stringham HM, McCarthy MI, Boehnke M, Tuomilehto J, Haiman C, Groop L, Atzmon G, Wilson JG, Neuberg D, Altshuler D, Ebert BL. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014 Dec 25;371(26):2488-98. doi: 10.1056/NEJMoa1408617. Epub 2014 Nov 26.</citation>
    <PMID>25426837</PMID>
  </reference>
  <reference>
    <citation>Weidner H, Rauner M, Trautmann F, Schmitt J, Balaian E, Mies A, Helas S, Baschant U, Khandanpour C, Bornhäuser M, Hofbauer LC, Platzbecker U. Myelodysplastic syndromes and bone loss in mice and men. Leukemia. 2017 Apr;31(4):1003-1007. doi: 10.1038/leu.2017.7. Epub 2017 Jan 11.</citation>
    <PMID>28074069</PMID>
  </reference>
  <reference>
    <citation>Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach C, Silverman LR; International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009 Mar;10(3):223-32. doi: 10.1016/S1470-2045(09)70003-8. Epub 2009 Feb 21.</citation>
    <PMID>19230772</PMID>
  </reference>
  <reference>
    <citation>Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mufti G, Mittelman M, Muus P, Te Boekhorst P, Sanz G, Del Cañizo C, Guerci-Bresler A, Nilsson L, Platzbecker U, Lübbert M, Quesnel B, Cazzola M, Ganser A, Bowen D, Schlegelberger B, Aul C, Knight R, Francis J, Fu T, Hellström-Lindberg E; MDS-004 Lenalidomide del5q Study Group. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood. 2011 Oct 6;118(14):3765-76. doi: 10.1182/blood-2011-01-330126. Epub 2011 Jul 13.</citation>
    <PMID>21753188</PMID>
  </reference>
  <reference>
    <citation>Mallo M, Luño E, Sanzo C, Cervera J, Haase D, Schanz J, García-Manero G, del Cañizo C, Sanz GF, Solé F. Clinical impact of the clone size in MDS cases with monosomy 7 or 7q deletion, trisomy 8, 20q deletion and loss of Y chromosome. Leuk Res. 2011 Jun;35(6):834-6. doi: 10.1016/j.leukres.2011.01.003. Epub 2011 Jan 26.</citation>
    <PMID>21269692</PMID>
  </reference>
  <reference>
    <citation>Della Porta MG, Gallì A, Bacigalupo A, Zibellini S, Bernardi M, Rizzo E, Allione B, van Lint MT, Pioltelli P, Marenco P, Bosi A, Voso MT, Sica S, Cuzzola M, Angelucci E, Rossi M, Ubezio M, Malovini A, Limongelli I, Ferretti VV, Spinelli O, Tresoldi C, Pozzi S, Luchetti S, Pezzetti L, Catricalà S, Milanesi C, Riva A, Bruno B, Ciceri F, Bonifazi F, Bellazzi R, Papaemmanuil E, Santoro A, Alessandrino EP, Rambaldi A, Cazzola M. Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol. 2016 Oct 20;34(30):3627-3637. doi: 10.1200/JCO.2016.67.3616.</citation>
    <PMID>27601546</PMID>
  </reference>
  <reference>
    <citation>Gerstung M, Pellagatti A, Malcovati L, Giagounidis A, Porta MG, Jädersten M, Dolatshad H, Verma A, Cross NC, Vyas P, Killick S, Hellström-Lindberg E, Cazzola M, Papaemmanuil E, Campbell PJ, Boultwood J. Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes. Nat Commun. 2015 Jan 9;6:5901. doi: 10.1038/ncomms6901.</citation>
    <PMID>25574665</PMID>
  </reference>
  <reference>
    <citation>Gerstung M, Papaemmanuil E, Martincorena I, Bullinger L, Gaidzik VI, Paschka P, Heuser M, Thol F, Bolli N, Ganly P, Ganser A, McDermott U, Döhner K, Schlenk RF, Döhner H, Campbell PJ. Precision oncology for acute myeloid leukemia using a knowledge bank approach. Nat Genet. 2017 Mar;49(3):332-340. doi: 10.1038/ng.3756. Epub 2017 Jan 16.</citation>
    <PMID>28092685</PMID>
  </reference>
  <reference>
    <citation>Schneider RK, Ademà V, Heckl D, Järås M, Mallo M, Lord AM, Chu LP, McConkey ME, Kramann R, Mullally A, Bejar R, Solé F, Ebert BL. Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS. Cancer Cell. 2014 Oct 13;26(4):509-20. doi: 10.1016/j.ccr.2014.08.001. Epub 2014 Sep 18.</citation>
    <PMID>25242043</PMID>
  </reference>
  <reference>
    <citation>Platzbecker U, Germing U, Götze KS, Kiewe P, Mayer K, Chromik J, Radsak M, Wolff T, Zhang X, Laadem A, Sherman ML, Attie KM, Giagounidis A. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study. Lancet Oncol. 2017 Oct;18(10):1338-1347. doi: 10.1016/S1470-2045(17)30615-0. Epub 2017 Sep 1. Erratum in: Lancet Oncol. 2017 Oct;18(10):e562.</citation>
    <PMID>28870615</PMID>
  </reference>
  <reference>
    <citation>Platzbecker U, Hofbauer LC, Ehninger G, Hölig K. The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes. Leuk Res. 2012 May;36(5):525-36. doi: 10.1016/j.leukres.2012.01.006. Epub 2012 Feb 1. Review.</citation>
    <PMID>22300879</PMID>
  </reference>
  <reference>
    <citation>Platzbecker U, Schetelig J, Finke J, Trenschel R, Scott BL, Kobbe G, Schaefer-Eckart K, Bornhäuser M, Itzykson R, Germing U, Beelen D, Ehninger G, Fenaux P, Deeg HJ, Adès L; German MDS Study; Cooperative Transplant Study Group; Fred Hutchinson Cancer Research Center; Groupe Francophone des Myelodysplasies. Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine. Biol Blood Marrow Transplant. 2012 Sep;18(9):1415-21. doi: 10.1016/j.bbmt.2012.05.003. Epub 2012 May 11.</citation>
    <PMID>22579634</PMID>
  </reference>
  <reference>
    <citation>Park S, Hamel JF, Toma A, Kelaidi C, Thépot S, Campelo MD, Santini V, Sekeres MA, Balleari E, Kaivers J, Sapena R, Götze K, Müller-Thomas C, Beyne-Rauzy O, Stamatoullas A, Kotsianidis I, Komrokji R, Steensma DP, Fensterl J, Roboz GJ, Bernal T, Ramos F, Calabuig M, Guerci-Bresler A, Bordessoule D, Cony-Makhoul P, Cheze S, Wattel E, Rose C, Vey N, Gioia D, Ferrero D, Gaidano G, Cametti G, Pane F, Sanna A, Germing U, Sanz GF, Dreyfus F, Fenaux P. Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents. J Clin Oncol. 2017 May 10;35(14):1591-1597. doi: 10.1200/JCO.2016.71.3271. Epub 2017 Mar 28.</citation>
    <PMID>28350519</PMID>
  </reference>
  <reference>
    <citation>Lamarque M, Raynaud S, Itzykson R, Thepot S, Quesnel B, Dreyfus F, Rauzy OB, Turlure P, Vey N, Recher C, Dartigeas C, Legros L, Delaunay J, Visanica S, Stamatoullas A, Fenaux P, Adès L. The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience. Blood. 2012 Dec 13;120(25):5084-5. doi: 10.1182/blood-2012-09-453555. Erratum in: Blood. 2014 Jun 26;123(26):4152.</citation>
    <PMID>23243156</PMID>
  </reference>
  <reference>
    <citation>Itzykson R, Thépot S, Quesnel B, Dreyfus F, Beyne-Rauzy O, Turlure P, Vey N, Recher C, Dartigeas C, Legros L, Delaunay J, Salanoubat C, Visanica S, Stamatoullas A, Isnard F, Marfaing-Koka A, de Botton S, Chelghoum Y, Taksin AL, Plantier I, Ame S, Boehrer S, Gardin C, Beach CL, Adès L, Fenaux P; Groupe Francophone des Myelodysplasies(GFM). Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood. 2011 Jan 13;117(2):403-11. doi: 10.1182/blood-2010-06-289280. Epub 2010 Oct 12.</citation>
    <PMID>20940414</PMID>
  </reference>
  <reference>
    <citation>Fenaux P, Mufti GJ, Hellström-Lindberg E, Santini V, Gattermann N, Germing U, Sanz G, List AF, Gore S, Seymour JF, Dombret H, Backstrom J, Zimmerman L, McKenzie D, Beach CL, Silverman LR. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010 Feb 1;28(4):562-9. doi: 10.1200/JCO.2009.23.8329. Epub 2009 Dec 21.</citation>
    <PMID>20026804</PMID>
  </reference>
  <reference>
    <citation>Mallo M, Del Rey M, Ibáñez M, Calasanz MJ, Arenillas L, Larráyoz MJ, Pedro C, Jerez A, Maciejewski J, Costa D, Nomdedeu M, Diez-Campelo M, Lumbreras E, González-Martínez T, Marugán I, Such E, Cervera J, Cigudosa JC, Alvarez S, Florensa L, Hernández JM, Solé F. Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations. Br J Haematol. 2013 Jul;162(1):74-86. doi: 10.1111/bjh.12354. Epub 2013 Apr 25.</citation>
    <PMID>23614682</PMID>
  </reference>
  <reference>
    <citation>Mekinian A, Grignano E, Braun T, Decaux O, Liozon E, Costedoat-Chalumeau N, Kahn JE, Hamidou M, Park S, Puéchal X, Toussirot E, Falgarone G, Launay D, Morel N, Trouiller S, Mathian A, Gombert B, Schoindre Y, Lioger B, De Wazieres B, Amoura Z, Buchdaul AL, Georgin-Lavialle S, Dion J, Madaule S, Raffray L, Cathebras P, Piette JC, Rose C, Ziza JM, Lortholary O, Montestruc F, Omouri M, Denis G, Rossignol J, Nimubona S, Adès L, Gardin C, Fenaux P, Fain O. Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study. Rheumatology (Oxford). 2016 Feb;55(2):291-300. doi: 10.1093/rheumatology/kev294. Epub 2015 Sep 8.</citation>
    <PMID>26350487</PMID>
  </reference>
  <reference>
    <citation>Fraison JB, Mekinian A, Grignano E, Kahn JE, Arlet JB, Decaux O, Denis G, Buchdahl AL, Omouri M, Maigne G, Aouba A, Leon N, Berthier S, Liozon E, Park S, Gardin C, Lortholary O, Rossignol J, Fenaux P, Fain O, Braun T. Efficacy of Azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Res. 2016 Apr;43:13-7. doi: 10.1016/j.leukres.2016.02.005. Epub 2016 Feb 20.</citation>
    <PMID>26922775</PMID>
  </reference>
  <reference>
    <citation>Khaznadar Z, Boissel N, Agaugué S, Henry G, Cheok M, Vignon M, Geromin D, Cayuela JM, Castaigne S, Pautas C, Raffoux E, Lachuer J, Sigaux F, Preudhomme C, Dombret H, Dulphy N, Toubert A. Defective NK Cells in Acute Myeloid Leukemia Patients at Diagnosis Are Associated with Blast Transcriptional Signatures of Immune Evasion. J Immunol. 2015 Sep 15;195(6):2580-90. doi: 10.4049/jimmunol.1500262. Epub 2015 Aug 5.</citation>
    <PMID>26246143</PMID>
  </reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 12, 2019</study_first_submitted>
  <study_first_submitted_qc>November 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2019</study_first_posted>
  <last_update_submitted>November 20, 2019</last_update_submitted>
  <last_update_submitted_qc>November 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Somatic mutations</keyword>
  <keyword>Clonal hematopoiesis</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>Immune escape</keyword>
  <keyword>Innovative predictive models</keyword>
  <keyword>EuroBloodNet</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

